Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Positive 90.9%

Neg 0% Neu 0% Pos 90.9%

Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price target from $12 to $19.